Skip to main
FATE

Fate Therapeutics (FATE) Stock Forecast & Price Target

Fate Therapeutics (FATE) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 33%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Fate Therapeutics Inc. is positioned strongly in the biopharmaceutical sector, particularly with its focus on iPSC-derived cellular immunotherapies that facilitate off-the-shelf solutions, enabling cost-effective large-scale manufacturing and simplified genetic modifications. Recent clinical data from its FT819 program has shown promising results in treating patients with systemic lupus erythematosus (SLE), demonstrating significant improvements in disease metrics and patient-reported outcomes. These developments, coupled with the potential for redosing strategies, bolster the company's competitive edge and future prospects, contributing to a positive outlook for its stock.

Bears say

The analysis indicates a negative outlook for Fate Therapeutics due to several notable risks, including the potential failure of FT819 to demonstrate significant clinical efficacy compared to existing CAR-T therapies. Concerns regarding safety and immunogenicity, coupled with risks associated with partnerships and regulatory agency responses, further exacerbate these challenges. Additionally, the possibility of medium-term dilution raises further financial concerns for investors, potentially impacting stock performance.

Fate Therapeutics (FATE) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 33% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fate Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fate Therapeutics (FATE) Forecast

Analysts have given Fate Therapeutics (FATE) a Buy based on their latest research and market trends.

According to 6 analysts, Fate Therapeutics (FATE) has a Buy consensus rating as of Dec 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fate Therapeutics (FATE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.